Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 468NIH 87NETWORK 56INDUSTRY 38UNKNOWN 5OTHER_GOV 5FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 3enzalutamide 3Abiraterone Acetate 3apalutamide 2Topotecan 2Testosterone 2Itraconazole 2Docetaxel 2Cholecalciferol 2Celecoxib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zanubrutinib 1venetoclax 1talabostat 1sargramostim 1pasireotide 1olaparib 1leucoselect phytosome 1ibrutinib 1capivasertib 1acalabrutinib 1abiraterone 1Tablets 1Streptozocin 1Rituximab 1Radiosurgery 1Pluvicto 1PT-100 dipeptide 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × FED × Etoposide × Clear all
NCT00100477 2013-09-25

Use of Topotecan in Patients With Refractory Acute Leukemia

VA Office of Research and Development

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡